Novel creatine formulation exhibits similar serum creatine concentrations and pharmacokinetics to creatine monohydrate in healthy adults
- 1Applied Physiology Laboratory, Department of Exercise and Sport Science, University of North Carolina, Chapel Hill, SC, USA
Abstract
Background Creatine monohydrate (CrM) is the most widely studied creatine form, demonstrating robust efficacy, bioavailability, and safety. With creatine growing in popularity, alternative formulations of creatine have been developed to target solubility and to optimize absorption pharmacokinetics (PK), as well as to reduce gastrointestinal (GI) intolerability. The purpose of the current study was to evaluate the acute effects of a novel creatine monohydrate (OptiCreatineTM; CrO) compared to CrM on serum creatine PK and GI tolerability in healthy adults.Methods Healthy, recreationally active adults (age: 22 ± 3 years; males n = 8, females n = 9) consumed a single 5-gram dose of CrM or CrO across two separate visits following an overnight fast, in a randomized, double-blind, crossover design. Venous blood samples were collected at baseline and 30, 60, 90, 120, 180, 240, and 300 mins post-ingestion of their assigned treatment to assess serum creatine concentrations. PK parameters including peak concentration (Cmax), time to peak (Tmax), absorption rate constant (ka), elimination rate constant (kel; h−1), and area under the curve (AUC₀–T) were derived using nonlinear regression modeling. GI symptoms were assessed using validated questionnaires.Results There was no difference in serum creatine concentrations between CrM or CrO across all participants (p = 0.707), males (p = 0.318), or females (p = 0.996) at any time point. Serum creatine increased over time regardless of treatment (p < 0.0001). No differences were observed between CrM and CrO for Cmax (mean difference ± standard deviation (MD ± SD): 7.66 ± 50.37μM; p = 0.82), Tmax (MD ± SD: −0.04 ± 0.13 h; p = 0.54), ka (MD ± SD: −0.15 ± 0.45 h−1; p = 0.51), kel (MD ± SD: 0.01 ± 0.03 h−1; p = 0.61), or AUC₀–T (MD ± SD: 22.09 ± 160.57 μM·h; p = 0.74), with no sex × treatment interactions (p ≥ 0.05). Descriptive evaluation showed similar GI symptom profiles between conditions, with low frequency and minimal severity reported across both treatments.Conclusions A single 5-gram dose of CrO produced similar serum creatine and PK characteristics to CrM in healthy adults. These findings support CrO as a viable delivery option, with no significant differences in acute pharmacokinetic profiles or GI tolerability compared to CrM.
Related
- Load and breath-hold: impact of 7-day creatine monohydrate loading on breath-hold exercise performance — a double-blind randomized controlled trial
- Formononetin as a Natural Product-Derived Candidate for Diabetic Microvascular Complications: Mechanistic Evidence, Pharmacokinetics, Formulation Strategies, and Translational Barriers
- Pharmacokinetics, subject satisfaction, and tolerability of a novel oral iron formulation based on naturally occurring microalgae Spirulina platensis
- Selection of the optimal long-acting injectable formulation of ivermectin for use in humans to target malaria vectors in Western Africa: evaluation of pharmacokinetics and mosquitocidal efficacy in cattle under laboratory conditions
- Enteric Fever Presenting With Acute Bilateral Lower Limb Weakness due to Para Infectious Myopathy With Elevated Serum Creatine Kinase: A Case Report.
BibTeX
@article{delbiondo2026novel,
title = {{Novel creatine formulation exhibits similar serum creatine concentrations and pharmacokinetics to creatine monohydrate in healthy adults}},
author = {Gabrielle M. DelBiondo and Celia W. Gottlieb and Paul A. Baker and W. Mikey Johnson and Caroline G. Kelly and Abbie E. Smith-Ryan},
journal = {Journal of the International Society of Sports Nutrition},
year = {2026},
month = nov,
doi = {10.1080/15502783.2026.2745618},
url = {https://doi.org/10.1080/15502783.2026.2745618},
note = {CC BY},
}
RIS
TY - JOUR
TI - Novel creatine formulation exhibits similar serum creatine concentrations and pharmacokinetics to creatine monohydrate in healthy adults
AU - Gabrielle M. DelBiondo
AU - Celia W. Gottlieb
AU - Paul A. Baker
AU - W. Mikey Johnson
AU - Caroline G. Kelly
AU - Abbie E. Smith-Ryan
PY - 2026
DA - 2026/11/09
JO - Journal of the International Society of Sports Nutrition
DO - 10.1080/15502783.2026.2745618
UR - https://doi.org/10.1080/15502783.2026.2745618
AB - Background Creatine monohydrate (CrM) is the most widely studied creatine form, demonstrating robust efficacy, bioavailability, and safety. With creatine growing in popularity, alternative formulations of creatine have been developed to target solubility and to optimize absorption pharmacokinetics (PK), as well as to reduce gastrointestinal (GI) intolerability. The purpose of the current study was to evaluate the acute effects of a novel creatine monohydrate (OptiCreatineTM; CrO) compared to CrM on serum creatine PK and GI tolerability in healthy adults.Methods Healthy, recreationally active adults (age: 22 ± 3 years; males n = 8, females n = 9) consumed a single 5-gram dose of CrM or CrO across two separate visits following an overnight fast, in a randomized, double-blind, crossover design. Venous blood samples were collected at baseline and 30, 60, 90, 120, 180, 240, and 300 mins post-ingestion of their assigned treatment to assess serum creatine concentrations. PK parameters including peak concentration (Cmax), time to peak (Tmax), absorption rate constant (ka), elimination rate constant (kel; h−1), and area under the curve (AUC₀–T) were derived using nonlinear regression modeling. GI symptoms were assessed using validated questionnaires.Results There was no difference in serum creatine concentrations between CrM or CrO across all participants (p = 0.707), males (p = 0.318), or females (p = 0.996) at any time point. Serum creatine increased over time regardless of treatment (p < 0.0001). No differences were observed between CrM and CrO for Cmax (mean difference ± standard deviation (MD ± SD): 7.66 ± 50.37μM; p = 0.82), Tmax (MD ± SD: −0.04 ± 0.13 h; p = 0.54), ka (MD ± SD: −0.15 ± 0.45 h−1; p = 0.51), kel (MD ± SD: 0.01 ± 0.03 h−1; p = 0.61), or AUC₀–T (MD ± SD: 22.09 ± 160.57 μM·h; p = 0.74), with no sex × treatment interactions (p ≥ 0.05). Descriptive evaluation showed similar GI symptom profiles between conditions, with low frequency and minimal severity reported across both treatments.Conclusions A single 5-gram dose of CrO produced similar serum creatine and PK characteristics to CrM in healthy adults. These findings support CrO as a viable delivery option, with no significant differences in acute pharmacokinetic profiles or GI tolerability compared to CrM.
SN - 1550-2783
ER -